Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03408171 · ClinicalTrials.gov registry record · NA

Comparison of 19g FNA and 19g FNB Needles for EUS-LB

A NA study, sponsored by Geisinger Clinic.

Completed
Registry status
NA
Development phase
40
Enrollment target

NCT03408171 is a NA study that has completed, run by Geisinger Clinic. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03408171, a NA study, has completed, sponsored by Geisinger Clinic.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

Chronic liver disorders (CLD) are a major cause of morbidity and mortality for individuals in the US. Though serologic analysis will often lead to a conclusive diagnosis, liver biopsy remains an important method for helping to determine the etiology and stage of LD. Percutaneous liver biopsy (PLB), transjugular liver biopsy (TLB) and surgical liver biopsy (SLB) are alternative methods for obtaining hepatic tissue. In recent years endoscopic ultrasound guided-liver biopsy (EUS-LB) has come to the forefront as a safe and effective method for obtaining tissue in CLD. There are several studies of the safety of EUS-LB as well as the adequacy of specimens obtained in this fashion. Most studies involve a 19-g needle, therefore in this study we hope to compare the tissue yields of a 19-g fine needle biopsy (FNB) needle, in comparison to conventional 19-g fine needle aspiration (FNA) needle. We predict that 19-g FNA and 19-g FNB needle will demonstrate similar diagnostic accuracy, with less visible blood artifact. Similarly, we predict the safety to be equal.

Interventions

  • DEVICE 19-gauge FNA needle
  • DEVICE 19-gauge FNB needle

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2017-10-02
Est. Completion 2018-08-17
Phase NA

Sponsor

Geisinger Clinic

107 total trials

What the Registry Record Tells You About NCT03408171

The ClinicalTrials.gov registry entry for NCT03408171 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geisinger Clinic, which has 107 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which 19-gauge FNA needle is the first listed.

NCT03408171 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03408171 about?

NCT03408171 is a clinical study titled "Comparison of 19g FNA and 19g FNB Needles for EUS-LB". Chronic liver disorders (CLD) are a major cause of morbidity and mortality for individuals in the US. Though serologic analysis will often lead to a conclusive diagnosis, liver biopsy remains an important method for helping to determine the etiology and stage of LD. Percutaneous liver biopsy (PLB), ...

What is the current status of trial NCT03408171?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2017-10-02. Estimated completion is 2018-08-17.

What interventions are being tested in trial NCT03408171?

The interventions under investigation include: 19-gauge FNA needle (DEVICE), 19-gauge FNB needle (DEVICE).

Who is sponsoring clinical trial NCT03408171?

This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.